MindBio Therapeutics (XCNQ:MBIO) Cash Flow from Financing : C$0.75 Mil (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is MindBio Therapeutics Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Mar. 2024, MindBio Therapeutics paid C$0.00 Mil more to buy back shares than it received from issuing new shares. It received C$0.00 Mil from issuing more debt. It paid C$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received C$0.00 Mil from paying cash dividends to shareholders. It received C$0.00 Mil on other financial activities. In all, MindBio Therapeutics spent C$0.00 Mil on financial activities for the three months ended in Mar. 2024.

MindBio Therapeutics Cash Flow from Financing Historical Data

The historical data trend for MindBio Therapeutics's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MindBio Therapeutics Cash Flow from Financing Chart

MindBio Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

Cash Flow from Financing

5.03

0.93

MindBio Therapeutics Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash Flow from Financing	Get a 7-Day Free Trial					0.40	0.50	0.25	-	-

MindBio Therapeutics Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

MindBio Therapeutics's Cash from Financing for the fiscal year that ended in Jun. 2023 is calculated as:

	Cash Flow from Financing		(A: Jun. 2023 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	1.024	+	0	+	-0.096	+	0	+	0	+	-0.001
=	0.93

MindBio Therapeutics's Cash from Financing for the quarter that ended in Mar. 2024 is:

	Cash Flow from Financing		(Q: Mar. 2024 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	0	+	0	+	0	+	0	+	0
=	0.00

Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.75 Mil.

MindBio Therapeutics (XCNQ:MBIO) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

MindBio Therapeutics's issuance of stock for the three months ended in Mar. 2024 was C$0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

MindBio Therapeutics's repurchase of stock for the three months ended in Mar. 2024 was C$0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

MindBio Therapeutics's net issuance of debt for the three months ended in Mar. 2024 was C$0.00 Mil. MindBio Therapeutics received C$0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

MindBio Therapeutics's net issuance of preferred for the three months ended in Mar. 2024 was C$0.00 Mil. MindBio Therapeutics paid C$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

MindBio Therapeutics's cash flow for dividends for the three months ended in Mar. 2024 was C$0.00 Mil. MindBio Therapeutics received C$0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

MindBio Therapeutics's other financing for the three months ended in Mar. 2024 was C$0.00 Mil. MindBio Therapeutics received C$0.00 Mil on other financial activities.

MindBio Therapeutics Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of MindBio Therapeutics's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

MindBio Therapeutics (XCNQ:MBIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MindBio Therapeutics Corp (XCNQ:MBIO) » Definitions » Cash Flow from Financing

Comparable Companies

Traded in Other Exchanges

WF6:Germany

Address

91-97 William Street, Level 4, Melbourne, VIC, AUS, 3000

Website

https://www.mindbiotherapeutics.com

MindBio Therapeutics Corp is pioneering clinical studies into the microdosing of psychedelic medicines to treat a range of medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opiate addictions. Its clinical trials microdosing of psychedelic medicines provide hope for sufferers of mental health conditions with new emerging treatment alternatives. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough microdosing studies. Geographically, the activities of the company takes place in Australia.